文献速递白血病MDS 与骨髓增殖性肿瘤

经治疗的继发性急性髓系白血病:一种预后不良的高危AML亚型

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis.
PubMed 文献 · Blood Adv · 2017-07-19

本研究将经治疗的继发性急性髓系白血病(ts-AML)定义为既往诊断骨髓增生异常、骨髓增殖性肿瘤或再生障碍性贫血且至少接受过1种治疗,按年龄<60岁或≥60岁分组评估缓解率和总生存期。结果显示ts-AML生存期短于未治疗AHD的s-AML,且年轻ts-AML生存期劣于del(5/7)、TP53、3q异常和治疗相关AML组,提示ts-AML为极高危亚型。

要点

  • ts-AML定义为AHD诊断后至少接受1种治疗,完全缓解率年轻组32%、老年组24%。
  • ts-AML总生存期显著短于未治疗AHD的s-AML(4.2 vs 9.2个月,P<.001)。
  • 年轻ts-AML生存期劣于del(5/7)、TP53、3q异常和治疗相关AML组(P<.01)。

核心结论

  • ts-AML代表极高危AML亚型,即使在年轻患者中预后也差。
  • s-AML应进一步分类以描述ts-AML,该亚型对当前治疗方案反应较差。
  • 未来AML试验设计应将ts-AML作为独立亚组。

研究设计与样本

  • 研究将ts-AML定义为既往诊断骨髓增生异常、骨髓增殖性肿瘤或再生障碍性贫血且至少接受1种治疗。
  • 按年龄<60岁或≥60岁分组,评估各治疗方案的缓解率和总生存期。
  • 生存结局与其他高危预后亚组进行比较。

主要发现

  • 完全缓解率和8周死亡率在年轻组分别为32%和27%,在老年组分别为24%和19%。
  • ts-AML与未治疗AHD的s-AML相比,总生存期4.2 vs 9.2个月(P<.001)。
  • ts-AML总生存期在年轻组和老年组分别为5个月和4.7个月。
  • 年轻AML中,ts-AML总生存期劣于del(5/7)、TP53、3q异常和治疗相关AML组(中位5 vs 7.9、7.8、7.9和11.2个月,P<.01)。
  • ts-AML内附加不良核型与更差结局相关(总生存期范围1.6-2.8个月)。

关键数值与推荐

  • ts-AML定义:既往诊断骨髓增生异常、骨髓增殖性肿瘤或再生障碍性贫血,且至少接受1种治疗。
  • 年龄分组:<60岁或≥60岁。
  • 完全缓解率:年轻组32%,老年组24%。
  • 8周死亡率:年轻组27%,老年组19%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Secondary acute myeloid leukemia (s-AML) includes therapy-related AML and AML evolving from antecedent hematological disorder (AHD). s-AML arising after treating AHD likely represents a prognostically distinct, high-risk disease category. In this study, treated s-AML (ts-AML) was defined by: (1) prior diagnosis of myelodysplasia, myeloproliferative neoplasm, or aplastic anemia and (2) at least 1 therapy for that diagnosis. ts-AML was categorized by age (< or ≥60 years), and each cohort assessed for response rates and overall survival (OS) on various treatment regimens. Survival outcomes were compared against other high-risk prognostic subsets. Results showed that complete response and 8-week mortality rates were 32% and 27% in the younger, and 24% and 19% in the older age groups, respectively. There was a significant OS difference within s-AML based on prior treatment of AHD (ie, ts-AML vs s-AML with untreated AHD, 4.2 vs 9.2 months; P < .001). Survival in ts-AML was poor across both cohorts (younger and older, 5 and 4.7 months, respectively). In younger AML, survival was significantly inferior in ts-AML when compared with deletion 5/7, TP53, 3q abnormality, and therapy-related AML groups (median, 5 vs 7.9, 7.8, 7.9, and 11.2 months, respectively; P < .01). Additional adverse karyotype within ts-AML was associated with even worse outcomes (OS range, 1.6-2.8 months). ts-AML represents a very high-risk category, even in younger AML patients. s-AML should be further classified to describe ts-AML, an entity less responsive to currently applied treatment approaches. Future AML trial designs should accommodate ts-AML as a distinct subgroup.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Boddu P, Kantarjian HM, Garcia-Manero G, et al. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017. PMID: 29296774. doi:10.1182/bloodadvances.2017008227

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。